FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382011895> ?p ?o ?g. }

• W4382011895 endingPage "768" @default.
• W4382011895 startingPage "762" @default.
• W4382011895 abstract "To investigate the value of pre-treatment albumin/fibrinogen ratio (AFR) on the prognosis of patients with diffuse large B-cell lymphoma (DLBCL).The data of DLBCL patients in the Affiliated Hospital of North Sichuan Medical College from April 2014 to March 2021 were retrieved, and 111 newly diagnosed patients who completed at least 4 cycles of R-CHOP or R-CHOP-like chemotherapy with complete data were included in the study. The clinical, laboratory examination and follow-up data of the patients were collected, and the receiver operating characteristic curve (ROC) was drawn according to patients' AFR before treatment and the survival status at the end of the follow-up, which could be used to preliminarily evaluate the predictive value of AFR for disease progression and patients' survival outcome. Furthermore, the correlation of AFR with the clinical and laboratory characteristics, progression-free survival (PFS) and overall survival (OS) was analyzed, and finally, univariate and multivariate Cox proportional hazard regression models were used to analyze factors affecting PFS and OS of DLBCL patients.The ROC curve indicated that AFR level had a moderate predictive value for PFS and OS in DLBCL patients, with the area under the curve (AUC) of 0.616 (P =0.039) and 0.666 (P =0.004), respectively, and the optimal cut-off values were both 9.06 for PFS and OS. Compared with high-AFR (≥9.06) group, the low-AFR (<9.06) group had a higher proportion of patients with Lugano III-IV stage ( P <0.001), elevated lactate dehydrogenase (P =0.007) and B symptoms (P =0.038). The interim analysis of response showed that the overall response rate (ORR) in the high-AFR group was 89.7%, which was significantly higher than 62.8% in the low-AFR group (P =0.001). With a median follow-up of 18.5 (3-77) months, the median PFS of the high-AFR group was not reached, which was significantly superior to 17 months of the low-AFR group (P =0.009). Similarly, the median OS of high-AFR group was not reached, either, which was significantly superior to 48 months of the low-AFR group (P < 0.001). In multivariate Cox regression analysis, AFR <9.06 was an independent risk factor both for PFS and OS (HRPFS=2.047, P =0.039; HROS=4.854, P =0.001).Pre-treatment AFR has a significant value for the prognosis evaluation in newly diagnosed DLBCL patients.弥漫大B细胞淋巴瘤患者治疗前白蛋白与纤维蛋白原比值在疾病预后判断中的价值.探讨治疗前白蛋白与纤维蛋白原的比值（AFR）对弥漫大B细胞淋巴瘤（DLBCL）患者预后的影响。.检索川北医学院附属医院2014年4月至2021年3月的DLBCL患者资料，将至少完成4周期R-CHOP或R-CHOP样化疗方案且资料完整的111例初诊患者纳入研究。收集患者的临床、实验室检查及随访数据，根据患者治疗前AFR及随访截止时的生存状态绘制受试者工作特征曲线（ROC），初步判断AFR对疾病进展和生存结局的预测价值，进一步分析AFR与患者临床及实验室检查特征、无进展生存（PFS）及总体生存（OS）情况的相关性，最后采用单因素及多因素Cox风险比例回归模型分析影响患者PFS及OS的因素。.ROC曲线显示，治疗前AFR水平对DLBCL患者的PFS和OS均有一定的预测价值，曲线下面积（AUC）分别为0.616（P =0.039）和0.666（P =0.004），最佳预测截断值均为9.06；相较于高AFR（≥9.06）组，低AFR（<9.06）组患者有更高比例的Lugano分期III-IV期（P < 0.001）、乳酸脱氢酶增高（P =0.007）及伴B症状的患者（P =0.038）。对患者进行中期疗效评估，高AFR组患者总体治疗反应率为89.7%，显著高于低AFR组患者的62.8%（P =0.001）；中位随访时间18.5（3-77）个月，高AFR组患者的中位PFS未达到，显著优于低AFR组的17个月（P =0.009）；高AFR组患者的中位OS未达到，亦显著优于低AFR组患者的47个月（P <0.001）。多因素Cox回归分析显示，AFR<9.06是影响患者PFS和OS的独立危险因素（HRPFS=2.047，P =0.039；HROS=4.854，P =0.001）。.治疗前AFR对初诊DLBCL患者的疾病预后具有较好的判断价值。." @default.
• W4382011895 created "2023-06-27" @default.
• W4382011895 creator A5026394330 @default.
• W4382011895 creator A5029377314 @default.
• W4382011895 creator A5032389152 @default.
• W4382011895 creator A5036776757 @default.
• W4382011895 creator A5066599847 @default.
• W4382011895 creator A5077530804 @default.
• W4382011895 date "2023-06-01" @default.
• W4382011895 modified "2023-10-18" @default.
• W4382011895 title "[Prognostic Value of Pre-treatment Albumin/Fibrinogen Ratio in Patients with Diffuse Large B-cell Lymphoma]." @default.
• W4382011895 doi "https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.03.021" @default.
• W4382011895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37356937" @default.
• W4382011895 hasPublicationYear "2023" @default.
• W4382011895 type Work @default.
• W4382011895 citedByCount "0" @default.
• W4382011895 crossrefType "journal-article" @default.
• W4382011895 hasAuthorship W4382011895A5026394330 @default.
• W4382011895 hasAuthorship W4382011895A5029377314 @default.
• W4382011895 hasAuthorship W4382011895A5032389152 @default.
• W4382011895 hasAuthorship W4382011895A5036776757 @default.
• W4382011895 hasAuthorship W4382011895A5066599847 @default.
• W4382011895 hasAuthorship W4382011895A5077530804 @default.
• W4382011895 hasConcept C126322002 @default.
• W4382011895 hasConcept C143998085 @default.
• W4382011895 hasConcept C146357865 @default.
• W4382011895 hasConcept C151730666 @default.
• W4382011895 hasConcept C181199279 @default.
• W4382011895 hasConcept C185592680 @default.
• W4382011895 hasConcept C207103383 @default.
• W4382011895 hasConcept C2776694085 @default.
• W4382011895 hasConcept C2777318727 @default.
• W4382011895 hasConcept C2778559949 @default.
• W4382011895 hasConcept C2779338263 @default.
• W4382011895 hasConcept C2779725641 @default.
• W4382011895 hasConcept C2780739268 @default.
• W4382011895 hasConcept C44249647 @default.
• W4382011895 hasConcept C50382708 @default.
• W4382011895 hasConcept C55493867 @default.
• W4382011895 hasConcept C58471807 @default.
• W4382011895 hasConcept C71924100 @default.
• W4382011895 hasConcept C86803240 @default.
• W4382011895 hasConcept C90924648 @default.
• W4382011895 hasConceptScore W4382011895C126322002 @default.
• W4382011895 hasConceptScore W4382011895C143998085 @default.
• W4382011895 hasConceptScore W4382011895C146357865 @default.
• W4382011895 hasConceptScore W4382011895C151730666 @default.
• W4382011895 hasConceptScore W4382011895C181199279 @default.
• W4382011895 hasConceptScore W4382011895C185592680 @default.
• W4382011895 hasConceptScore W4382011895C207103383 @default.
• W4382011895 hasConceptScore W4382011895C2776694085 @default.
• W4382011895 hasConceptScore W4382011895C2777318727 @default.
• W4382011895 hasConceptScore W4382011895C2778559949 @default.
• W4382011895 hasConceptScore W4382011895C2779338263 @default.
• W4382011895 hasConceptScore W4382011895C2779725641 @default.
• W4382011895 hasConceptScore W4382011895C2780739268 @default.
• W4382011895 hasConceptScore W4382011895C44249647 @default.
• W4382011895 hasConceptScore W4382011895C50382708 @default.
• W4382011895 hasConceptScore W4382011895C55493867 @default.
• W4382011895 hasConceptScore W4382011895C58471807 @default.
• W4382011895 hasConceptScore W4382011895C71924100 @default.
• W4382011895 hasConceptScore W4382011895C86803240 @default.
• W4382011895 hasConceptScore W4382011895C90924648 @default.
• W4382011895 hasIssue "3" @default.
• W4382011895 hasLocation W43820118951 @default.
• W4382011895 hasOpenAccess W4382011895 @default.
• W4382011895 hasPrimaryLocation W43820118951 @default.
• W4382011895 hasRelatedWork W150915388 @default.
• W4382011895 hasRelatedWork W1946250925 @default.
• W4382011895 hasRelatedWork W2012238656 @default.
• W4382011895 hasRelatedWork W2021276212 @default.
• W4382011895 hasRelatedWork W2032099400 @default.
• W4382011895 hasRelatedWork W2283115812 @default.
• W4382011895 hasRelatedWork W2755661484 @default.
• W4382011895 hasRelatedWork W2934192929 @default.
• W4382011895 hasRelatedWork W4312173599 @default.
• W4382011895 hasRelatedWork W2183308400 @default.
• W4382011895 hasVolume "31" @default.
• W4382011895 isParatext "false" @default.
• W4382011895 isRetracted "false" @default.
• W4382011895 workType "article" @default.